Latest Lenalidomide Stories
In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd. London,UK (PRWEB) October 01, 2013 Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib)...
- The offense of persistently instigating lawsuits, typically groundless ones.
- Sale or purchase of positions in church or state.